third-generation, irreversible EGFR-TKI that selectively inhibits both EGFR-TKIesensitizing and EGFR T790M resistance mutations, with lower activity against wild-type EGFR. Method: To describe the first natural history protocol regarding the use of Osimertinib in Chilean patients with the diagnosis of lung cancer with the EGFR mutation and progression to tyrosine kinase inhibitors with detectable T790 mutation. We also included patients with de novo T790 mutation. We evaluated demographic data, diagnostic method of resistance, sites of progression, toxicities and treatment efficacy Results: We analyzed 28 patients in the period of June 2016 and April 2018. Median age was 65 years old, female sex corresponded to 36%; PS 0,1 96%, 7% of patients were de novo T790 mutations, 93% patients had a history of EGFR-TKI therapy, gefitinib in 3 patients, erlotinib in 15 pts, and afatinib in 8 pts. Upon the initial evaluation 86% patients were diagnosed with stage IV NSCLC Central nervous system (CNS) lesions were observed in 6 patients (21%). T790M was confirmed by histologic evaluation in 16 patients and by Liquid biopsy in 12 patients. The response rate, disease control rate progression free and overall survival will be presented in a later publication. Conclusion: In our very early experience with the use of osimertinib, we report a relatively similar patient characteristics compared with the registration studies of Osimertinib. At the moment adhesion and tolerance profile compares favorable with older generation TKI inhibitors. 
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